<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HE47E0848BD344393BB06595147D0E04C" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 4879 IH: Research for All Act of 2014</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2014-06-17</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 4879</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20140617">June 17, 2014</action-date>
			<action-desc><sponsor name-id="C000754">Mr. Cooper</sponsor> (for himself and <cosponsor name-id="L000571">Mrs. Lummis</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited review of drugs and
			 biological products to provide safer or more effective treatment for males
			 or females, to amend the Public Health Service Act to enhance the
			 consideration of sex differences in basic and clinical research, and for
			 other purposes.</official-title>
	</form>
	<legis-body id="H607C8B09E29144CB8EE517707606B5C0" style="OLC">
		<section id="H0ED4203DA0C143BDB19EED9E4E42F578" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Research for All Act of 2014</short-title></quote> .</text>
		</section><section id="H858535CCD39D40B5B6EF12448C72ECA7"><enum>2.</enum><header>Sufficiency of design and size of clinical trials during expedited review</header><text display-inline="no-display-inline">The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs,
			 shall review and develop policies, as appropriate, to ensure that the
			 design and size of clinical trials for products granted expedited approval
			 pursuant to section 506 of the Federal Food, Drug, and Cosmetic Act (21
			 U.S.C. 356) are sufficient to determine the safety and effectiveness of
			 such products for men and women using subgroup analysis.</text>
		</section><section commented="no" id="H4271D1369C104A68A35B0404B1E67C99"><enum>3.</enum><header>Expedited review of drugs and biological products to provide safer or more effective treatment for
			 males or females</header>
			<subsection commented="no" id="H9174E6CFCEA94E5D88669AF016DCC1BB"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 506 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356</external-xref>) is amended by adding at the
			 end the following:</text>
				<quoted-block display-inline="no-display-inline" id="H734E89297AE94928903284C5FA0F78C5" style="OLC">
					<subsection commented="no" id="HC64882702A874118BD713C55417D327F"><enum>(g)</enum><header>Expedited review of drugs and biological products To provide safer or more effective treatment for
			 males or females</header>
						<paragraph commented="no" id="H7F301E53687E428AB81A9AF527087D5F"><enum>(1)</enum><header>Eligible product</header><text display-inline="yes-display-inline">The Secretary shall, at the request of the sponsor of a new drug, facilitate the development and
			 expedite the review of such drug if the drug—</text>
							<subparagraph id="H03C2EB3CA79340019DE6FE17F4A88019"><enum>(A)</enum><text>is intended—</text>
								<clause id="HE2169123429947F9A6CDA9C6FAAE4231"><enum>(i)</enum><text>to avoid serious adverse events; or</text>
								</clause><clause id="H82531B0F9B524C97A2ECA40B50847EF5"><enum>(ii)</enum><text>to treat a serious or life-threatening disease or condition;</text>
								</clause></subparagraph><subparagraph commented="no" id="HC8860359DDEF47A7A066F2A6F4EBE0AC"><enum>(B)</enum><text display-inline="yes-display-inline">whether alone or in combination with one or more other drugs or biological products, is intended
			 for safer or more effective treatment for men or women than a currently
			 available product approved to treat the general population or the other
			 sex; and</text>
							</subparagraph><subparagraph id="HECACFD07E87844248E369DD9D8FBF6AD"><enum>(C)</enum><text display-inline="yes-display-inline">is supported by results of clinical trials that include and separately examine outcomes for both
			 men and women.</text>
							</subparagraph></paragraph><paragraph commented="no" id="HEBAD5577252D4FE5ADADED18D7676608"><enum>(2)</enum><header>Designation</header><text display-inline="yes-display-inline">At the request of the sponsor of an eligible product described in paragraph (1), the Secretary
			 shall designate the drug as an expedited product to provide safer or more
			 effective treatment for males or females.</text>
						</paragraph><paragraph commented="no" id="HBD1F2DEB5D1540D99FD401CD25631E98"><enum>(3)</enum><header>Early and frequent communication</header><text display-inline="yes-display-inline">The Secretary shall, with respect to each expedited product designated under this subsection,
			 provide early and frequent communication and review of incomplete
			 applications to the same extent and in the same manner as is provided
			 under subsections (b) and (d).</text>
						</paragraph><paragraph commented="no" id="H72A8E2BC0C1F49448E9BA3604ACADBE5"><enum>(4)</enum><header>Rule of construction</header><text>Nothing in this subsection shall be construed—</text>
							<subparagraph commented="no" id="HB7E2D1D440F5420FA0F9360958221B73"><enum>(A)</enum><text>to lessen or otherwise alter the standard of safety and effectiveness required for the approval or
			 licensing of drugs or biological products under section 505 of this Act or
			 section 351 of the Public Health Service Act; or</text>
							</subparagraph><subparagraph commented="no" id="H87047D57D11A4F4F9DE2E6E7DCB18D84"><enum>(B)</enum><text display-inline="yes-display-inline">to authorize application of the provisions of subsection (c) (relating to the use of surrogate
			 endpoints) to expedited products designated under this subsection.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
			</subsection><subsection commented="no" id="H9A2042B9F4F849BE901B2432B18E2DE8"><enum>(b)</enum><header>Technical corrections</header><text display-inline="yes-display-inline">Subsection (f) of section 506 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356</external-xref>) (relating
			 to awareness efforts), as designated by section 902(a) of Public Law
			 112–144, is amended—</text>
				<paragraph commented="no" id="H0CEE86AD8944478BA962413066B2BA19"><enum>(1)</enum><text>in paragraph (1), by striking <quote>and and</quote> and inserting <quote>and</quote>; and</text>
				</paragraph><paragraph commented="no" id="HC66E84A2DF384A4CA4FAFD81A360DB9A"><enum>(2)</enum><text>by moving such subsection (f) so that it follows subsection (e) of such section 506.</text>
				</paragraph></subsection></section><section id="HC4B888CBD31D4DBDAD6728CF83C15986"><enum>4.</enum><header>Research on sex differences</header>
			<subsection id="H723A19DF90804041B134A499AFC61BE1"><enum>(a)</enum><header>Inclusion in NIH research</header>
				<paragraph id="H2F9FC28CFB354A429C17AD82E5BAAFC6"><enum>(1)</enum><header>In general</header><text>Section 492B of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/289a-2">42 U.S.C. 289a–2</external-xref>) is amended—</text>
					<subparagraph id="HDCB2BDB67E494DB597A41B6907222C88"><enum>(A)</enum><text>by redesignating subsections (b) through (g) as subsections (c) through (h), respectively; and</text>
					</subparagraph><subparagraph id="HA8A0C7C3F40C4EB8B044356BBAB3EA38"><enum>(B)</enum><text>by inserting after subsection (a) the following:</text>
						<quoted-block display-inline="no-display-inline" id="H34C32714D25340A784994641BA233D0E" style="OLC">
							<subsection id="H2B91283BD3174627B04B7C54E7DFDC58"><enum>(b)</enum><header>Inclusion of sex differences in basic research</header>
								<paragraph id="HEE63EDF3F1724ED9A7DBC5B980B07E89"><enum>(1)</enum><header>Applicability to basic research</header>
									<subparagraph id="H42E054605C89407FAB3B2C01033A221B"><enum>(A)</enum><header>In general</header><text>The Director of NIH shall determine when it is appropriate for projects of basic research involving
			 cells, tissues or animals to include both male and female cells, tissues,
			 or animals.</text>
									</subparagraph><subparagraph id="HB07FDF039B644E7890CAAAE4B1F035C1"><enum>(B)</enum><header>Deadline for initial determination; updates</header><text>The Director of NIH—</text>
										<clause id="H0112826746C54BF4B7843CF289D9194F"><enum>(i)</enum><text>shall make the initial determinations required by subparagraph (A) not later than one year after
			 the date of enactment of the <short-title>Research for All Act of 2014</short-title>; and</text>
										</clause><clause id="H2511BEB66C17448284F8FEFEE9674F9C"><enum>(ii)</enum><text>may subsequently update or revise such determinations as the Director determines appropriate.</text>
										</clause></subparagraph><subparagraph id="H2FAB14ACF7E949DE8596B6BEC4ECCB53"><enum>(C)</enum><header>Consultation</header><text>In making the initial determinations required by subparagraph (A), the Director of NIH—</text>
										<clause id="H78C0D73687994CBDA962491EEDCB84B1"><enum>(i)</enum><text>shall consult with the Office of Research on Women's Health, the Institute of Medicine, the Office
			 of Laboratory Animal Welfare, and appropriate members of the scientific
			 and academic communities; and</text>
										</clause><clause id="HDEF7C85DD9FB4C099FFB65131A17A148"><enum>(ii)</enum><text display-inline="yes-display-inline">may conduct outreach and educational initiatives within the scientific and academic communities on
			 the influence of sex as a variable in basic research in order to develop a
			 consensus within such communities on when it is appropriate for projects
			 of basic research involving cells, tissues or animals to include both male
			 and female cells, tissues, or animals.</text>
										</clause></subparagraph></paragraph><paragraph id="HF2B417CD50D1420580D87B9F27355407"><enum>(2)</enum><header>Inclusion</header><text>Beginning on the date that is 1 year after the date of enactment of the <short-title>Research for All Act of 2014</short-title>, in conducting or supporting basic research in accordance with paragraph (1), the Director of NIH
			 shall, subject to paragraph (3), ensure that—</text>
									<subparagraph id="H865E5D37070A45BFBAAA910FF192D91B"><enum>(A)</enum><text>in the case of research on cells or tissues—</text>
										<clause id="H96F71F97D2E442719A08C632E4BD1696"><enum>(i)</enum><text>cells or tissues, as applicable, are derived from both male and female organisms in each project of
			 such research; and</text>
										</clause><clause id="HA5BEF65B47F945EB8D001916EDBD7CD7"><enum>(ii)</enum><text>the results are disaggregated according to whether the cells or tissues are derived from male or
			 female organisms; and</text>
										</clause></subparagraph><subparagraph id="H8D0E60343C3D48719B04B295230F3279"><enum>(B)</enum><text>in the case of animal research—</text>
										<clause id="HAC8CC1F2A41649D28F41BB04757E7F43"><enum>(i)</enum><text>both male and female animals are included as subjects in each project of such research; and</text>
										</clause><clause id="HD386270D4C3642ACBC43E9BCD7533838"><enum>(ii)</enum><text>the results are disaggregated according to whether the subjects are male or female.</text>
										</clause></subparagraph></paragraph><paragraph id="HCE31A647B13F4717995BAC56C53817E9"><enum>(3)</enum><header>Exception</header><text>Paragraph (2) shall not apply to a project of basic research if the Director of NIH determines that
			 the inclusion of cells or tissues derived from both male and female
			 organisms, or the inclusion of both male and female animals as subjects,
			 as applicable, is inappropriate in the case of such project.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
					</subparagraph></paragraph><paragraph id="H1FB6F87971D04AB6A9797F32CEEEEF9A"><enum>(2)</enum><header>Design of research</header><text display-inline="yes-display-inline">Subsection (d) of section 492B of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/289a-2">42 U.S.C. 289a–2</external-xref>), as
			 redesignated, is amended—</text>
					<subparagraph id="H07007819C25A4F28BDC3C851C5D9FFB0"><enum>(A)</enum><text>by striking <quote>(d)</quote> and all that follows through <quote>In the case</quote> and inserting the following:</text>
						<quoted-block display-inline="no-display-inline" id="HECFCB6BF82F5478BA7722603BFC2A392" style="OLC">
							<subsection id="H84CC20430E3043DF93F8CCA811166B28"><enum>(d)</enum><header>Design of research</header>
								<paragraph id="H8BF8FDD559C94EFAB4B5873721A1F947"><enum>(1)</enum><header>Clinical trials</header><text>In the case</text></paragraph></subsection><after-quoted-block>; and</after-quoted-block></quoted-block>
					</subparagraph><subparagraph id="HE50B69A8C5BA4F9B99138E9D5C030260"><enum>(B)</enum><text>by adding at the end the following:</text>
						<quoted-block display-inline="no-display-inline" id="H866078030A5A4CF6A54FA79E80AB185E" style="OLC">
							<paragraph id="HFFCD1EF531B74007A45A39DB1281971A"><enum>(2)</enum><header>Basic research</header><text display-inline="yes-display-inline">In the case of basic research in which cells or tissues derived from both male and female organisms
			 will be included in accordance with subsection (b)(2)(A) or both male and
			 female animals will be included as subjects in accordance with subsection
			 (b)(2)(B), the Director of NIH shall ensure that sex differences are
			 examined and analyzed, as appropriate.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
					</subparagraph></paragraph><paragraph id="HEA3ADEBD966D44C39537DBB876F73222"><enum>(3)</enum><header>Updating guidelines for clinical and basic research</header><text display-inline="yes-display-inline">Section 492B(f)(1) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/289a-2">42 U.S.C. 289a–2</external-xref>), as redesignated, is amended
			 to read as follows:</text>
					<quoted-block display-inline="no-display-inline" id="H3393ADF687B94C24ABA0655041C068CF" style="OLC">
						<paragraph id="HF72432B61B5A4310BC89B38E86E3D9B0"><enum>(1)</enum><header>Date certain; update</header><text display-inline="yes-display-inline">The guidelines required in subsection (e) regarding the requirements of this section for clinical
			 and basic research shall—</text>
							<subparagraph id="H1B7E2BA6CFDF4BE8A82F72716D155FB0"><enum>(A)</enum><text>be updated and published in the Federal Register not later than 1 year after the date of enactment
			 of the <short-title>Research for All Act of 2014</short-title>;</text>
							</subparagraph><subparagraph id="HC730871D15F949A4B686FDE589D210A8"><enum>(B)</enum><text display-inline="yes-display-inline">reflect the growing understanding that sex differences matter;</text>
							</subparagraph><subparagraph id="HC3CB12E121FD472DB0C4097F02E293E3"><enum>(C)</enum><text>ensure better enforcement of the requirements of this section by the personnel of the agencies of
			 the National Institutes of Health responsible for reviewing grant
			 proposals; and</text>
							</subparagraph><subparagraph id="HF76B594DE4E54995AEF191D5C2403D24"><enum>(D)</enum><text>include guidance on when research strongly supports or strongly negates the conclusion that there
			 is a significant difference in how the variables being studied affect
			 women or members of minority groups, as the case may be, relative to how
			 such variables affect other subjects in the research.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
				</paragraph><paragraph id="H538FE23B97704831BEF6C6A509737AAC"><enum>(4)</enum><header>Applicability</header><text display-inline="yes-display-inline">Section 492B(f)(2) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/289a-2">42 U.S.C. 289a–2</external-xref>), as redesignated, is amended
			 by adding at the end the following: <quote>For fiscal year 2016 and subsequent fiscal years, the Director of NIH may not approve any proposal
			 of basic research to be conducted or supported by any agency of the
			 National Institutes of Health unless the proposal specifies the manner in
			 which the research will comply with this section.</quote>.</text>
				</paragraph><paragraph id="HBE996B0DF6984436BF9502D7FFB31A72"><enum>(5)</enum><header>Conforming changes</header><text display-inline="yes-display-inline">Section 492B of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/289a-2">42 U.S.C. 289a–2</external-xref>) is amended—</text>
					<subparagraph commented="no" id="H21FFAD1EE40944DBA49371F601215CC5"><enum>(A)</enum><text>in the heading of subsection (a), by striking <quote><header-in-text level="subsection" style="OLC">Requirement of inclusion</header-in-text></quote> and inserting <quote><header-in-text level="subsection" style="OLC">Inclusion in clinical research</header-in-text></quote>;</text>
					</subparagraph><subparagraph id="H70620D03D90144E39DEC5D2B6B7E39BB"><enum>(B)</enum><text>in subsection (a)(1), by striking <quote>subsection (b)</quote> and inserting <quote>subsection (c)</quote>;</text>
					</subparagraph><subparagraph id="HBCBABD5AD5834F5D816169D9734069AC"><enum>(C)</enum><text>in subsection (e)(1)(A), as redesignated, by striking <quote>subsection (b)</quote> and inserting <quote>subsection (c)</quote>;</text>
					</subparagraph><subparagraph id="HCA8AC5582C544910BC83E069EFD9E8D6"><enum>(D)</enum><text>in subsection (e)(1)(B), as redesignated, by striking <quote>subsection (c)</quote> and inserting <quote>subsection (d)</quote>; and</text>
					</subparagraph><subparagraph id="HE7E03C6E897244BFAEA006195C91A466"><enum>(E)</enum><text>in subsection (e)(2), as redesignated, by striking <quote>subsection (b)</quote> and inserting <quote>subsection (c)</quote>.</text>
					</subparagraph></paragraph></subsection><subsection id="H824EB87DF0A1464DA59F543520FC56B6"><enum>(b)</enum><header>Biennial reports of Director of NIH</header><text>Subparagraph (C) of section 403(a)(4) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/283">42 U.S.C. 283(a)(4)</external-xref>) is
			 amended—</text>
				<paragraph id="H50B7B67F22204E8DAAF98B7FD4E81AE9"><enum>(1)</enum><text>by redesignating clause (vi) as clause (vii); and</text>
				</paragraph><paragraph id="H8DCEFFB9C8CA43CABBDDC4FF906682A2"><enum>(2)</enum><text>by inserting after clause (v) the following:</text>
					<quoted-block display-inline="no-display-inline" id="H0E7DBA5F3317440DB2D3B73696C88C98" style="OLC">
						<clause id="H2F494473B00D4E8EA8212482CA9FD8BE"><enum>(vi)</enum><text display-inline="yes-display-inline">Basic research, including a breakdown of the sex of organisms from which cells and tissues are
			 derived, a breakdown of the sex of animal subjects, and such other
			 information as may be necessary to demonstrate compliance with section
			 492B (regarding sex differences in basic research).</text></clause><after-quoted-block>.</after-quoted-block></quoted-block>
				</paragraph></subsection><subsection id="H82A2C74184D34CF9A66EE731CC3FC5DE"><enum>(c)</enum><header>Special Centers of Research on Sex Differences</header><text>Part H of title IV of the Public Health Service Act is amended by inserting after section 492B of
			 such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/289a-2">42 U.S.C. 289a–2</external-xref>) the following:</text>
				<quoted-block display-inline="no-display-inline" id="H3B03E309D26D4A6A8ADBE728270B66EA" style="OLC">
					<section id="HDEB2C6204A584AE78094D3B3999BACFB"><enum>492C.</enum><header>Special Centers of Research on Sex Differences</header><text display-inline="no-display-inline">The Secretary may award grants or other support to entities for the continued operation and
			 expansion of Special Centers of Research on Sex Differences.</text></section><after-quoted-block>.</after-quoted-block></quoted-block>
			</subsection><subsection id="HCECA3DAEC447433FA041F90B8888FC4E"><enum>(d)</enum><header>Rule of construction</header><text>Nothing in this Act or the amendments made by this Act shall be construed to lessen any standard or
			 requirement set forth in part 1, 2, or 3 of subchapter A of chapter I of
			 title 9, Code of Federal Regulations.</text>
			</subsection></section><section id="H26CA2C26A7574A4D947EC7207512D332"><enum>5.</enum><header>GAO reports</header><text display-inline="no-display-inline">Not later than 1 year after the date of enactment of the <short-title>Research for All Act of 2014</short-title>, the Comptroller General of the United States shall—</text>
			<paragraph id="H81BCF71C76984446A502CDAC042B28DD"><enum>(1)</enum><text>submit to the Congress updated versions of the reports of the Government Accountability Office
			 entitled <quote>Women’s Health: NIH Has Increased Its Efforts To Include Women in Research</quote> (published in May 2000; GAO/HEHS–00–96) and <quote>Women’s Health: Women Sufficiently Represented in New Drug Testing, But FDA Oversight Needs
			 Improvement</quote> (published in July 2001; GAO–01–754); and</text>
			</paragraph><paragraph id="HA327FA4DA37F43D7BFAFA2AFDCC7CA4C"><enum>(2)</enum><text display-inline="yes-display-inline">in such updated reports—</text>
				<subparagraph id="H1151A8F2A16A4CF7B47BFC7E5695318C"><enum>(A)</enum><text>examine the inclusion of women, female animals, and female-derived cells and tissues in federally
			 funded research over the past decade;</text>
				</subparagraph><subparagraph id="HACF90283C2E840EFBB65389E8D49A3EC"><enum>(B)</enum><text>examine how Federal agencies report and analyze subgroup information and translate any differences
			 to the medical community and patients;</text>
				</subparagraph><subparagraph id="HE8A3CF39C9F24C1CB815E517C4C82D7D"><enum>(C)</enum><text>determine whether the quality of care which women receive is being negatively impacted by inclusion
			 rates in basic and clinical research; and</text>
				</subparagraph><subparagraph id="HE515E5D9E7F74B36A14A3C58EBEFCD16"><enum>(D)</enum><text>address current efforts within National Institutes of Health and other government agencies to
			 encourage the sharing of research data on sex differences and evaluate
			 mechanisms to improve such sharing, including a publicly accessible online
			 system that will conform with policies protecting commercial, proprietary,
			 or private information.</text>
				</subparagraph></paragraph></section></legis-body>
</bill>


